Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: TP-7 · Selank acetate
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Synthetic peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Experimental anxiolytic and enkephalin-related effects.
Evidence and critical reading
Reported scientific and empirical uses
Cognition and neurology
Handbooks describe anxiolytic/nootropic uses and alternation with Semax. Claims of no dependence, tolerance or interactions require their own long-term evidence.
Human evidence
A 62-person comparator report does not establish equivalence to modern standard care or the Semax/Selank stack.
Preclinical evidence
Neurochemical findings are not proof of long-term anxiety control.
Critical reading and limitations
A study compared Selank with medazepam in 62 participants. Its abstract does not establish formal equivalence, sustained superiority or mixture safety. Nasal bottle concentration alone does not determine quantity per spray or drop.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
300–1000 mcg · Amount per administration
- Frequency
- Source proposes daily or alternating twice weekly.
- Duration
- Not stated on selected page.
- Route
- Subcutaneous
- Context
- Described anxiety/nootropic use; do not attribute to acetylated/amidated variants.
- Presentation
- 5- or 10-mg lyophilized vials; also mentions a separate nasal formulation.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual01 · Page 121 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
250–1000 mcg · Amount per administration
- Frequency
- 1–2 times daily per source.
- Duration
- 14–30 days; two-week break per source.
- Route
- Intranasal
- Context
- Described anxiolytic/nootropic use.
- Presentation
- Not stated on selected page.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual07 · Page 43 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Long-term safety and interactions are incompletely characterized; acetylated/amidated analogues require separate evidence.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID18454096 · Small active-comparator study
Generalized anxiety/neurasthenia.
Route not verified in the selected abstract.
Anxiolytic effects described as similar to medazepam.
No formal equivalence or long-term safety demonstration.
n = 62
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Selank · 2 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT05832060 · Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With DyslexiaRegistry status: UnknownLast update posted: September 15, 2023Query verification: October 16, 2026
NCT01747200 · Effects of Transcranial Magnetic Stimulation on Object RecognitionRegistry status: CompletedLast update posted: July 2, 2017Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID18454096
Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB.
October 16, 2026
- R06
- R20
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026